21 results about "Predictive marker" patented technology

The invention discloses a prediction marker and a prediction method for acute upper respiratory infection susceptibility. The prediction marker and the prediction method are used for solving the problem that current acute upper respiratory infection susceptibility risk prediction is low in accuracy. The method comprises the following steps: firstly, providing a prediction marker for acute upper respiratory infection susceptibility, wherein the prediction marker is a prediction feature combination obtained by comprehensively considering human health state blood routine data and baseline blood transcriptome data and carrying out feature processing; secondly, providing a prediction method, and obtaining a to-be-detected blood sample; and performing blood analysis based on a to-be-detected blood sample, inputting the obtained blood routine sample and the gene expression sample into a susceptibility prediction model pre-trained based on a prediction marker for susceptibility risk judgment, and obtaining a susceptibility risk assessment result of acute upper respiratory infection of a human body corresponding to the to-be-detected blood sample in a future period of time, therefore, the acute upper respiratory infection susceptibility risk of the human body in a period of time in the future can be simply, quickly and accurately predicted.

The present invention provides various methods for screening one or more compounds, suitably using non-invasive visual methods and neural networks for generating predicted fluorescence images of cells, to assess an effect of the compound on the cell, as well as to classify a compound or to determine an activity of a compound. Also provided are systems and methods for carrying out such assessments.

The invention discloses an application of intestinal flora metabolite salicylic acid as a predictive marker of Escherichia coli calf diarrhea. The obviously up-regulated metabolite salicylic acid is screened out from the diarrhea calf feces through a non-targeted metabonomics technology, and in a group of new independent samples, it is verified through an ELISA test that the salicylic acid concentration of the diarrhea calf feces is obviously higher than that of a healthy group. ROC curve analysis shows that the area under curve (AUC) of SA for predicting escherichia coli calf diarrhea is 0.8148, and the method has good prediction capability. The invention provides a non-invasive, cheap, rapid and high-specificity prediction method, can be used for early warning and auxiliary diagnosis of Escherichia coli calf diarrhea, and has important significance for guiding clinical precise medication and reducing the death rate of calves.

The present disclosure provides improved methods of treating endometrial cancer or ovarian cancer in a subject using levels of combinations of biomarkers as predictive markers for response to CDK2 inhibitors and combinations with CDK2 inhibitors.

The invention discloses a predictive marker as well as a related product and application thereof, and relates to the field of tumor diagnosis. The invention finds that WNT5A can be used as a marker of any one or more of disease risk, prognosis risk, disease progress, treatment effect, residual focus and metastatic focus of squamous-cell carcinoma, is beneficial to accurate diagnosis and treatment of squamous-cell carcinoma, and accelerates the research and development of new drugs.

The object of the present invention is the use of glycosphingolipid biosynthesis inhibitors for the treatment of tumors that are dependent on the oncogene GOLPH3 as well as on two oncogenes similar to GOLPH3 (GOLPH3-L and LCS, which form a GOLPH3 cluster with GOLPH3). Another object of the invention is the use of GOLPH3 genomic amplification detection as a predictive marker for identifying tumors responsive to said inhibitor.

The invention particularly discloses a predictive marker for treating acute myelogenous leukemia on double-negative T cells, and relates to the technical field of biological medicines. The CD96 can be used as an intervention target point insensitive to DNT treatment of the AML patient, the killing effect of DNT on primary cells of the AML patient can be enhanced by specifically knocking out the CD96 or combining the CD96 with a CD96 specific blocking agent Nelistotug, and the insensitivity of DNT treatment of the AML patient is improved.

The invention discloses a predictive marker for improving the blood sugar effect through exercise intervention of a type 2 diabetes patient and application of the predictive marker. The predictive marker is formed by combining the following metabolite markers: creatine, spermidine, 4-oxo-tretinoin, S-methylcysteine sulfoxide, 3-phosphoglyceric acid / 2-phosphoglycerol, vitamin C3-sulfosulfone, salicyloyl urea glucuronide and gamma-glutamyl isoleucine, and the metabolite markers are used for detecting the content of the metabolite markers. The method is used for predicting the movement intervention of overweight or obese type 2 diabetes patients to improve the blood sugar obviously, the treatment efficiency is improved, and the application of precision medicine in type 2 diabetes management is realized.

The invention relates to an ankylosing spondylitis curative effect prediction marker of an interleukin 17A inhibitor and application of the ankylosing spondylitis curative effect prediction marker. The marker for predicting the curative effect of the ankylosing spondylitis of the interleukin 17A inhibitor, disclosed by the invention, comprises a lysosome related membrane protein 3 (LAMP3) and 11 beta-hydroxysteroid dehydrogenase (HSD11B1).

The invention belongs to the technical field of biological medicine, and provides an immunotherapy response prediction marker RBM28 and application thereof in combined treatment sensitization, the application is characterized in that the expression level of RBM28 is used as an evaluation index, a TG003 and PD-1 or ATO and PD-1 combined inhibitor is used for in-vitro treatment of esophageal squamous carcinoma tumor cells and mouse models, and the immunotherapy response prediction marker RBM28 can be used for immunotherapy sensitization. The immunotherapy prediction effect of the RBM28 expression level as an evaluation index on the esophageal squamous cell carcinoma and the treatment effect of the TG003 and PD-1 or ATO and PD-1 combined inhibitor on the esophageal squamous cell carcinoma are evaluated; results show that high expression of RBM28 is related to development of various tumors, and RBM28 can be used as an immunotherapy response prediction marker; the inhibitor can be used for jointly treating esophageal squamous cell carcinoma, inhibiting RBM28 phosphorylation, inducing immune activation, enhancing the curative effect of immunotherapy and remarkably reducing the tumor volume so as to achieve the purpose of treating esophageal squamous cell carcinoma.

The invention belongs to the field of biological medicine, and particularly relates to ICAM1 serving as a marker for predicting the therapeutic effect of a glioblastoma PD-1 monoclonal antibody and combined therapy application of the ICAM1. The ICAM1 not only can be used as a potential biomarker for predicting the treatment effect of the anti-PD-1 antibody, but also can be used as an important target in a combined immunotherapy strategy; the ICAM1 antibody and PD-1 monoclonal antibody combined treatment can become a novel immune intervention means for improving the prognosis of GBM patients. Therefore, the ICAM1 can be used as a predictive marker for the treatment effect of the glioblastoma PD-1 monoclonal antibody, and the ICAM1 blocking and combining with the PD-1 monoclonal antibody has high clinical transformation value.

According to the application of the serological biomarker in preparation of the vulnerable plaque diagnostic kit, the serological biomarker comprises sTREM2. Human peripheral blood serum is collected, and the concentration of soluble myeloid cell triggered receptor 2 (sTREM2) in the serum is determined by using an enzyme-linked immunosorbent assay (ELISA) kit or an equivalent immunoassay method, so that early discovery and (dynamic) monitoring of vulnerable plaques are realized. Through verification, the sTREM2 is suitable for being used as a diagnosis and prediction marker of vulnerable plaque related diseases, and guidance is provided for further clinical diagnosis (such as OCT / IVUS) and treatment.

The invention provides an application of 5, 6-EET as a predictive marker of triple negative breast cancer pulmonary metastasis, and 5, 6-EET promotes triple negative breast cancer pulmonary metastasis. And 5, 6-EET promotes lung metastasis of triple-negative breast cancer by enhancing the permeability of pulmonary vessels. The 5, 6-EET promotes TNBC cells to generate pulmonary parenchyma metastasis by enhancing the permeability of mouse pulmonary vessels, and the discovery helps people to understand the scientific significance of arachidonic acid metabolism reprogramming in the TNBC pulmonary metastasis process, clarifies the molecular mechanism of 5, 6-EET metabolism in the TNBC pulmonary metastasis process, and provides a potential reference index for predicting the pulmonary metastasis risk.

This invention belongs to the field of biomedical technology and discloses oral bacterial biomarkers related to colorectal cancer and their applications. This invention provides oral bacterial biomarkers associated with the prognosis of colorectal cancer, wherein the bacteria include at least one of *Campylobacter gracilis*, *Neisseria oralis*, and *Treponema medium*. It also provides the application of the above-mentioned oral bacterial biomarkers as prognostic predictive markers for colorectal cancer, and the application of reagents for detecting oral bacteria in the preparation of products predicting the prognosis of colorectal cancer. Through in-depth research, this invention has discovered that some oral bacteria are significantly correlated with the progression of colorectal cancer and can effectively predict the progression and prognosis of colorectal cancer, providing a reference for the prognosis of colorectal cancer and offering a promising target and direction for the future diagnosis and treatment of colorectal cancer.

The invention discloses a diabetes cognitive impairment prediction marker combination based on a blood proteome risk scoring model and application of the diabetes cognitive impairment prediction marker combination, and the marker combination is composed of seven proteins, namely NEFL, WFDC2, PTX3, EXTL1, FGF23, ENO3 and PPME1. The marker combination disclosed by the invention is high in specificity for recognizing cognitive impairment of T2D people and excellent in prediction performance. Compared with PET (Polyethylene Terephthalate) inspection, expensive instruments and equipment are not needed; compared with cerebrospinal fluid examination, risks caused by lumbar puncture can be avoided. The method has extremely high reference value for prediction and targeted therapy intervention of T2D cognitive impairment, and is suitable for popularization and application.

The present invention relates to a method of predicting the clinical outcome of a subject diagnosed with epithelial cancer, such as oral squamous cell carcinoma, and biomarkers for use in the method.

The present application relates to the use of plasma osteocalcin as a biomarker in the preparation of a diagnostic and / or prognostic product for sepsis in children. The prognostic product uses the measurement of osteocalcin levels on the first day of admission of a child with sepsis to assess the degree of organ dysfunction and the need for organ support in patients with sepsis. The present application discloses the potential of osteocalcin as a modulator of the immune inflammatory response in sepsis and that its level changes can be used as a predictive marker of the diagnosis and clinical outcome of sepsis. This finding provides a new biomarker for the early diagnosis, prognosis evaluation and treatment of sepsis and an important basis for clinical management.

To identify a factor that serves as an efficacy prediction marker for a substance recognizing transferrin receptor (TfR), or provide a method for predicting efficacy using the marker, or to provide an agent containing a substance recognizing TfR to be administered to a subject for whom efficacy has been predicted by the marker.SOLUTION: There are provided use of L-type amino acid transporter 1 (LAT1) or mTOR as an index for predicting the efficacy of a substance recognizing transferrin receptor (TfR); a method for predicting the efficacy of a substance recognizing TfR, the method comprising analyzing expression of LAT1 or expression of a gene encoding LAT1 in a sample derived from a subject, or analyzing activity of mTOR; and an agent comprising a substance recognizing TfR for administration to a subject for whom the efficacy of the agent has been predicted to be effective using LAT1 or mTOR as an index.SELECTED DRAWING: None

The invention discloses a whole genome molecular marker group for predicting the grain width of corn grains and application of the whole genome molecular marker group. The predictive marker group is composed of 215 SNP molecular markers, and the genomic position of each marker is shown in an attached table. The marker group can be used for genome prediction of the corn grain width character, the prediction accuracy can reach about 70%, and the marker group has wide applicability and meets the requirement for efficient and precise breeding of corn. A prediction system constructed based on the marker group can be applied to grain width prediction of double haploid (DH) lines, breeding early generation materials and hybrids, early genotype screening is achieved, and materials with poor grain width performance are effectively eliminated. The method can significantly reduce the field phenotype identification workload, reduce the breeding cost, shorten the breeding period and accelerate the genetic progress, and provides an efficient technical tool for corn molecular design breeding and genome selection.

The application discloses an application of inducing sputum CC16 as a prediction marker of COPD severity and eosinophil subtype. The application finds that the expression of CC16 in induced sputum of mild and moderate COPD patients and severe and very severe COPD patients has significant difference by detecting and analyzing various inflammatory molecules in induced sputum, and can distinguish eosinophilic COPD. The application establishes a regression model based on FEV1pred% and the relative expression level of CC16 mRNA, and the model has good sensitivity, specificity and accuracy. Therefore, the mRNA level of induced sputum CC16 has good application prospect for evaluating the severity of COPD and diagnosing the eosinophil subtype. The application can evaluate the severity of COPD and diagnose the eosinophil subtype in a more simple way, and based on the characteristics of the biomarker, a more reliable non-invasive kit can be prepared.